LYRA:NASDAQLyra Therapeutics, Inc. Analysis

Lyra Therapeutics is on the brink of delisting after voluntarily filing Form 25 with Nasdaq, a material development that compounds its already precarious financial position. The company reports a ‑98.5% max drawdown, a 30‑day volatility of 95%, and a beta exceeding 1.4, indicating extreme price swings. Cash on hand ($15.9 M) is far outweighed by debt ($30.3 M) and a negative operating cash flow of $28.9 M, while margins are deeply negative (gross margin ‑152%).
Technical signals offer no relief: the 20‑day SMA (0.72) sits above the 50‑day SMA (0.64) but both are far below the 200‑day SMA (3.46), the RSI at 47 signals a neutral stance, and the MACD histogram is barely positive, suggesting only a marginal bullish bias that is unlikely to overcome the fundamental tailwinds.